Bright Minds Biosciences Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| DRUG.CN | ANRO | MPLT | ATAI | LBRX | SPRB | |
|---|---|---|---|---|---|---|
| Market cap | 257.55M | 914.34M | 372.91M | — | 1.32B | 133.96M |
| P/E (TTM) | — | — | — | — | 408.5 | — |
| Forward P/E | -3.4 | -7.3 | -2.0 | — | -7.6 | 9.4 |
| Price/book | 0.8 | 3.7 | 0.9 | — | 3.5 | 1.5 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −64.14% | +109.34% | −58.43% | — | +163.38% | −64.33% |
| Today | −29.58% | +2.64% | −1.47% | 0.00% | +1.29% | +8.88% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All DRUG.CN news ›Bright Minds Biosciences: Promising Catalysts Despite The FDA Setback
Bright Minds Biosciences’ further studies or protocol changes could become a path past the FDA’s recent hold decision. Read more on DRUG stock here. - Bright Minds Biosciences’ early epilepsy results support further R&D, although small…
Bright Minds Biosciences: Downgrade To 'Hold' On BMB-101 Setback DEE And Progression Into PWS
Bright Minds Biosciences is downgraded to "Hold" after the FDA placed a partial clinical hold on its BMB-101 IND for DEE. Click here to read more on DRUG. - Bright Minds Biosciences is downgraded from "Strong Buy" to "Hold" after the FDA…
Bright Minds Biosciences Provides Update About Planned Study with BMB-101 in Developmental and Epileptic Encephalopathies
The proposed trial related to this IND is a randomized, placebo-controlled, double-blind Phase 2 study designed to evaluate the efficacy and safety of ascending doses of BMB-101, up to a maximum tolerated dose, for the treatment of…
Bright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)
The FDA cited mouse toxicity findings and insufficient pharmacokinetic and juvenile-toxicity data when it placed Bright Minds' planned Phase 2 BMB-101 epilepsy trial on partial clinical hold. An investigation is underway on behalf of DRUG…
Bright Minds Biosciences reports FDA partial hold on BMB‑101 seizure trial
The agency cited mouse toxicity and inadequate data for pediatric enrollment; the company is awaiting its full clinical hold letter. A planned U.S. seizure trial faces an FDA partial clinical hold after Bright Minds Biosciences Inc.…
Bright Minds Biosciences (NASDAQ:DRUG) Stock Price Up 6.6% – Here’s What Happened
Posted by Michael Walen on Oct 15th, 2026 Bright Minds Biosciences Inc. (NASDAQ:DRUG – Get Free Report) shares were up 6.6% on Thursday. The company traded as high as $53.56 and last traded at $54.0420. 7,996 shares were traded during…
More from 1 other outlet
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- investors.brightmindsbio.com1
- marketbeat.com1
- mugglehead.com1
- prnewswire.com1
- seekingalpha.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 7 articles, not a forecast.